Coalition for Epidemic Preparedness Innovations

Last updated

Coalition for Epidemic Preparedness Innovations
CEPI.svg
AbbreviationCEPI
FormationJanuary 2017;4 years ago (2017-01)
Founders
Founded at Davos, Switzerland [3]
PurposeFund vaccine development [3]
Headquarters Oslo, Norway
Locations
Chief executive
Richard J. Hatchett
Key people
Jane Halton (Chair)
Staff (2020)
68 [4]
Website CEPI.net

The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases (EID). [4] [5]

Contents

CEPI is focused on the World Health Organization's (WHO) "blueprint priority diseases", which include: the Middle East respiratory syndrome-related coronavirus (MERS-CoV), the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the Nipah virus, the Lassa fever virus, and the Rift Valley fever virus, as well as the Chikungunya virus and the hypothetical, unknown pathogen "Disease X". [6] [5] CEPI investment also requires "equitable access" to the vaccines during outbreaks, [7] although subsequent CEPI policy changes may have compromised this criteria. [8]

CEPI was conceived in 2015 and formally launched in 2017 at the World Economic Forum (WEF) in Davos, Switzerland. It was co-founded and co-funded with US$460 million from the Bill and Melinda Gates Foundation, the Wellcome Trust, [3] and a consortium of nations composed of India, [1] Germany, Japan and Norway, which the European Union (2019) and United Kingdom (2020) subsequently joined. [3] [5] CEPI is headquartered in Oslo, Norway. [4]

History

Founding

Jeremy Farrar, co-author of the concept of CEPI, and board member Jeremy Farrar C0058569 Wellcome Images.jpg
Jeremy Farrar, co-author of the concept of CEPI, and board member

The concept for CEPI was outlined in a July 2015 paper in The New England Journal of Medicine , titled "Establishing a Global Vaccine-Development Fund", co-authored by British medical researcher Jeremy Farrar (a director of Wellcome Trust), American physician Stanley A. Plotkin (co-discoverer of the Rubella vaccine), and American expert in infectious diseases Adel Mahmoud (developer of the HPV vaccine and rotavirus vaccine). [7] [9]

Their concept was further expanded at the 2016 WEF in Davos, where it was discussed as a solution to the problems encountered in developing and distributing a vaccine for the Western African Ebola virus epidemic. [3] Co-founder and funder, Bill Gates said: "The market is not going to solve this problem because epidemics do not come along very often — and when they do you are not allowed to charge some huge premium price for the tools involved". [3] CEPI's creation was also supported and co-funded by the pharmaceutical industry including GlaxoSmithKline (GSK), with CEO Sir Andrew Witty explaining at the WEF, "It is super-disruptive when the red phone rings in our vaccine division because of a health emergency. People do not realise that there's no spare capacity in the world's vaccine production system today". [3]

CEPI was formally launched at the 2017 WEF in Davos, with an initial investment of US$460 million by a consortium that included the governments of Norway, Japan, and Germany, The Wellcome Trust, and the Gates Foundation; [10] [3] India joined a short time afterwards. [11] [12] In a launch interview with the Financial Times (FT), Gates said that a key goal was to reduce the time to develop vaccines from 10 years to less than 12 months. [3]

The initial targets were the six EID viruses with known potential to cause major epidemics, being: MERS, Lassa fever, Nipah virus, Ebola, Marburg fever and Zika. [3] [5] The FT reported CEPI would "build the scientific and technological infrastructure for developing vaccines quickly against pathogens that emerge from nowhere to cause a global health crisis, such as Sars in 2002/03 and Zika in 2015/16", and fund research papers on the costs and process of vaccine development. [3] Town & Country listed it as one of the top-10 newsworthy moments from the 2017 Davos. [13] At launch, Norwegian physician John-Arne Røttingen, who led the steering committee for Ebola vaccine trials, served as interim CEO, and CEPI was based at the Norwegian Institute of Public Health in Oslo. [7]

In April 2017, Richard J. Hatchett, former director of the U.S. government's Biomedical Advanced Research and Development Authority (BARDA), became the full-time CEO. [14] Hatchett was also a member of the United States Homeland Security Council under George W. Bush, and the United States National Security Council, under Barack Obama. [15] [16] Also in April 2017, CEPI opened an additional office in London, and in October 2017, a further office was opened in Washington, D.C. [17] Nature later stated, "It is by far the largest vaccine development initiative ever against viruses that are potential epidemic threats". [18]

In 2020, CEPI was identified by several media outlets as a "key player in the race to develop a vaccine" for coronavirus disease 2019. [4] [19] [15]

Funding

At its launch in 2017, CEPI announced five-year financial pledges from its founders that amounted to US$460 million and came from the sovereign governments of Japan (US$125 million), Norway (US$120 million), and Germany (US$10.6 million in 2017 alone, and which later became US$90 million), and from global foundations of the Gates Foundation (US$100 million), and the Wellcome Trust (US$100 million); India was finalising their financial commitment, which was made shortly afterward. [20] A funding target of US$1 billion was set for the first 5 years of operation (i.e. by January 2022). [20] The journal Nature said of the amount raised that: "It is by far the largest vaccine development initiative ever against viruses that are potential epidemic threats". [18]

As part of its funding structure, CEPI has used "vaccine bonds" to "frontload" multi-year sovereign funding pledges. In 2019, the International Finance Facility for Immunisation (IFFIm) issued NOK 600 million in vaccine bonds to front-load the commitment by Norway, through Gavi, the Vaccine Alliance, to CEPI. [21] [22]

In March 2019, the European Commission granted access to CEPI into the EU's Horizon 2020 programme, and a longer-term financial funding programme. [23] CEPI note presentations that the EU's financial commitment amounts to US$200 million, which when added to the seed amount (including the full German commitment), came to US$740 million. [24]

By February 2020, Bloomberg News reported that CEPI had raised a total of US$760 million with additional donations from the governments of Australia, Belgium, Canada, and the U.K. [4] Bloomberg said that "CEPI solves what economists call a 'coordination problem'. It can help pair boutique research and development companies with big vaccine manufacturers, work with regulators to streamline approval processes and resolve patent disputes on the spot. Its scientific advisory committee has executives from Pfizer, Johnson & Johnson, and Japan's Takeda Pharmaceutical, among others". [4]

In March 2020, the British government pledged £210 million in funding to CEPI to specifically focus on a vaccine for the coronavirus; making Britain CEPI's largest individual donor. [25] [26]

2019 Contributions [27]
ContributorCategoryValue
million USD
Flag of Norway.svg  Norway Common Pool81.7
Flag of Germany.svg  Germany Common Pool39.3
Flag of Japan.svg  Japan Common Pool25.0
Bill & Melinda Gates Foundation Common Pool20.0
Flag of Europe.svg  EU Chik & RVF 18.4
Flag of the United Kingdom.svg  UK Common Pool13.0
Flag of Canada (Pantone).svg  Canada Common Pool7.5
Flag of Europe.svg  EU Ebola 3.7
Vulcan Inc. Ebola2.5
Flag of Australia (converted).svg  Australia Common Pool0.7
Wellcome Trust Common Pool0.1
Currency adjustment−0.9
Total211.0

Mission

The founding mission of CEPI was "equitable access" in pandemics: selling vaccines to developing nations at affordable prices. [8] Affordable access to existing patented vaccines had long been a concern for the medical community, and concern mounted in the wake of the struggle to get access to vaccine in the 2013–2016 Ebola epidemic. [28] [8] Averting a repetition of this crisis was the motivating factor behind founding CEPI. [9]

The struggle to get access to vaccine in the 2013-2016 Ebola epidemic was one of the factors motivating the creation of the CEPI Ebola Outbreak Map (ongoing).png
The struggle to get access to vaccine in the 2013–2016 Ebola epidemic was one of the factors motivating the creation of the CEPI

Policy changes

CEPI's original policy [29] contained specific measures to prevent some of these market problems. All vaccine-manufacturing contracts would need initial approval by a public review board. The policy also stated that vaccine prices would be set at levels affordable to those needing vaccines and sustainable to the manufacturer. [30] Trade secrets would not be funded by the CEPI. Companies had to share all research data developed with CEPI funds. While CEPI would, controversially, not retain and license the intellectual property developed with CEPI funds (allowing the groups awarded funding to own it), [31] the CEPI retained "step-in" rights: the right to license and use intellectual property developed with CEPI funds for vaccine production, even if the company that had received the funding and taken ownership of the IP later withdrew from the agreement with CEPI. [8] The original policy also required that funded parties pre-register any trials in a clinical trials registry, publish results within a year of study completion (except with compelling reason and permission of CEPI), publish results in open-access articles, and have mechanisms for securely sharing underlying data and results, including negative results, in a way that preserves trial volunteer privacy (see AllTrials for further information). [31]

Pharmaceutical corporations, including Johnson & Johnson, Pfizer, and Takeda, objected to the original policy, and these provisions were removed in December 2018, [32] [8] after the CEPI had obtained significant funding. [33] The policy changes met with strong criticism, led by Médecins Sans Frontières. [34] [35] CEPI was also criticized for not following its own policies on transparency, and for removing the requirement that CEPI's board review CEPI's contracts. [31] [36] [35]

The CEPI stated that its vaccines would continue to be affordable and available, [4] and published an article discussing the changes, saying that the old policy "while reflective of the idealism that inspired the creation of CEPI, was felt by others not to be pragmatic or reflect the business realities confronted by vaccine developers". [30] It said that several unnamed vaccine manufacturers had declared that they could not work with the CEPI under the original policy. It said that the policy change did not reflect a change in commitment to access, and CEPI would still retain the right to do research and development using intellectual property it had funded, if the old partner was unable to continue. It also said that the CEPI would retain the right to find a new manufacturer if the old manufacturer could not continue, provided the old manufacturer agrees to the transfer of the information and intellectual property to the new one. [30]

The New York Times said that CEPI had made a "failed effort to get large pharmaceutical firms to agree to be partners without insisting on substantial profits or proprietary rights to research that CEPI helped to finance and produce," and had replaced specific implementation measures with lip service to its funding mission. [8]

Reception

The coalition was nominated for the 2021 Nobel Peace Prize by Norwegian MP Carl-Erik Grimstad. [37] [38]

Structure

Richard J. Hatchett, CEO of CEPI from 2017 Dr Richard J. Hatchett (2011).jpg
Richard J. Hatchett, CEO of CEPI from 2017

CEPI is incorporated under Norwegian law. As of March 2020, [39] [5] a full-time staff of 68 [4] that runs the organisation under the direction of a chief executive officer, Richard Hatchett. [39]

Publications

In October 2018, CEPI scientists estimated that the costs of developing at least one vaccine for each of the diseases that could escalate into global humanitarian crises was between US$2.8 billion and US$3.7 billion. [40] In November 2019, CEPI discussed its target portfolio was on the WHO's "blueprint priority diseases", that included: MERS-CoV, Nipah virus, Lassa fever virus, and Rift Valley fever virus, as well as Chikungunya virus, and the WHO's Disease X. [6] CEPI outlined its projects to update CEPI priorities for establishment of technical and regulatory pathways for vaccine development, develop sustainable manufacturing solutions for vaccine candidates nearing completion, and create investigatory stockpiles of its vaccine candidates for use in emergency situations. [5]

Investments

General development

Specific vaccines

Lassa fever/MERS-CoV

TEM of Lassa virions Lassa virus.JPG
TEM of Lassa virions
  • In March 2018, US$37.5 million was given to Austrian-based Themis Bioscience to fund a vaccine against Lassa virus and MERS-CoV, using a measles vector technology. [41] [5]
  • In April 2018, US$56 million was given to U.S.-based Inovio Pharmaceuticals to fund a DNA-vaccine against Lassa virus and MERS-CoV. [42] [5]
  • In May 2018, US$54.9 million was given to the International AIDS Vaccine Initiative (IAVI), to fund a vaccine against Lassa virus via replication-competent vesicular stomatitis viral vector technology. [5]
  • In June 2018, US$35 million was given to U.S.-based Profectus Biosciences, to fund an attenuated "VesiculoVax" vaccine against Lassa virus. [5]
  • In August 2018, US$36 million was given to German-based IDT Biologika, to fund a vaccine against MERS-CoV (only) using a recombinant modified vaccinia Ankara viral vector technology. [5]
  • In September 2018, US$19 million to Janssen Pharmaceutica and the University of Oxford, to fund a vaccine against Lassa and MERS-Cov using a simian adenoviral vaccine viral vector technology. [5]

Nipah virus

  • In May 2018, US$25 million was given to U.S.-based Profectus Biosciences, to make a recombinant protein subunit vaccine against Nipah virus. [5]
  • In February 2019, US$31 million was given to the University of Tokyo, to develop a vaccine by inserting the Nipah-virus G gene ("Malaysia strain"), into a measles vector ("Edmonston B strain"). [5]
  • In August 2019, US$43.6 million was given to Public Health Vaccines LLC, to fund the development and manufacture of a vaccine using a recombinant vesicular stomatitis virus technology. [43] [5]

SARS-CoV-2

SEM of SARS-CoV-2 SARS-CoV-2 49531042877.jpg
SEM of SARS-CoV-2
  • In January 2020, CEPI funded three teams working on a vaccine for SARS-CoV-2, being: Moderna, Inovio Pharmaceuticals, and the University of Queensland (UQ). [44] [45] By February 2020, Inovio announced that it had produced a pre-clinical DNA-based vaccination to fight COVID-19 at its lab in San Diego. [46] Inovio collaborated with a Chinese firm to speed its acceptance by regulatory authorities in China for human trialing. [47] The strategy of the UQ team is to develop a molecular clamp vaccine that genetically modifies viral proteins to make them mimic the coronavirus and stimulate an immune reaction. [45] [44]
  • In January 2020, CEPI announced a fourth SARS-CoV-2 project in a collaboration with their existing partner CureVac, to develop and manufacture a vaccine. [48] CEPI's CEO, Richard J. Hachett said in an interview with the FT that CEPI expected to have human trials within 16 weeks, but cautioned "All these timelines are aggressive and aspirational. As circumstances unfold there may be opportunities to reduce the timing but it is critically important that any new vaccine is safe and effective". [15]
  • In February 2020, Bloomberg News, citing virologists, identified CEPI as a "key player in the race to develop a vaccine"; [4] a status other media outlets have attributed. [49] [15] In reviewing vaccine development on the virus Vox said: "CEPI is a large part of why there are already dozens of Covid-19 vaccine candidates making their way through animal and human trials, as well as platforms to develop more", [50] while The Guardian said CEPI was "leading efforts to finance and coordinate Covid-19 vaccine development". [19]
  • In March 2020, Hatchett gave an interview to Channel 4 News saying that "war is an appropriate analogy", for the steps needed to counter the virus, and that "this is the most frightening disease that I have ever encountered in my career, and that includes Ebola, it includes MERS, it includes SARS. And it's frightening because of the combination of infectiousness and a lethality that appears to be many-fold higher than flu". [51] Hatchett told The Daily Telegraph that coronaviruses are the most serious threat to public health since the Spanish flu, and that a vaccine will take up to 18 months to deliver at a cost of £1.5 billion. [52] CEPI said that its funds for fighting the virus would be fully allocated by the end of March and that it was launching a new funding call for US$2 billion to support fighting the virus. [53] [54] [55]
  • In March 2020, CEPI invested US$4.4 million in two more projects with Swedish vaccine laboratory Novavax, and with Oxford University, bringing its total investment in SARS-CoV-2 vaccine work to US$23.7 million, and announcing that it would invest up to US$100 million in further COVID-19 projects. [56]

Chikungunya virus

  • In June 2019, US$21 million was given to Themis Bioscience to fund phase 3 clinical trials and regulatory approval of a vaccine using measles viral vector technology. [5]
  • In July 2019, US$23.4 million was given to Austrian-based biotech Valneva SE to fund manufacturing and late-stage clinical development of a single-dose, live-attenuated vaccine. [5]

Rift Valley fever

  • In July 2019, US$12.5 million was given to Dutch-based Wageningen University and Research for a single-dose vaccine candidate for Rift Valley fever that uses an attenuated virus technology, which included: vaccine manufacturing, preclinical research, and a phase 1 study. [5]
  • In July 2019, US$9.5 million was given to Colorado State University for manufacturing and preclinical studies to assess another single-dose vaccine candidate against Rift Valley fever (also using an attenuated virus technology). [5]

See also

Related Research Articles

Lassa fever Viral disease spread by a type of mouse

Lassa fever, also known as Lassa hemorrhagic fever (LHF), is a type of viral hemorrhagic fever caused by the Lassa virus. Many of those infected by the virus do not develop symptoms. When symptoms occur they typically include fever, weakness, headaches, vomiting, and muscle pains. Less commonly there may be bleeding from the mouth or gastrointestinal tract. The risk of death once infected is about one percent and frequently occurs within two weeks of the onset of symptoms. Of those who survive, about a quarter have hearing loss, which improves within three months in about half of these cases.

Severe acute respiratory syndrome Disease caused by severe acute respiratory syndrome coronavirus

Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by severe acute respiratory syndrome coronavirus, the first identified strain of the SARS coronavirus species severe acute respiratory syndrome–related coronavirus (SARSr-CoV). The syndrome caused the 2002–2004 SARS outbreak. Around late 2017, Chinese scientists traced the virus through the intermediary of Asian palm civets to cave-dwelling horseshoe bats in Xiyang Yi Ethnic Township, Yunnan.

GeoVax is a clinical-stage biotechnology company initially established primarily to develop an effective and safe vaccine against many serious human diseases for which there are significant unmet medical needs. GeoVax’ novel development platform builds on the proven clinical and commercial success of the Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax technology approach uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated. In human clinical trials of the company’s HIV vaccines, GeoVax demonstrated that VLPs are safe and eliciting both strong and durable humoral and cellular immune response.

Biomedical Advanced Research and Development Authority Government organization in Washington D.C., United States

The Biomedical Advanced Research and Development Authority(BARDA) is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.

Novavax American biotechnology company

Novavax, Inc., is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for Ebola, influenza, respiratory syncytial virus (RSV), and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its vaccine for COVID-19. Novavax has indicated it recognizes a continued need for innovative vaccines in other therapeutic areas and reports it has taken steps to ensure continued advancement of its influenza vaccine.

Disease X Placeholder infectious disease name from the WHO

Disease X is a placeholder name that was adopted by the World Health Organization (WHO) in February 2018 on their shortlist of blueprint priority diseases to represent a hypothetical, unknown pathogen that could cause a future epidemic. The WHO adopted the placeholder name to ensure that their planning was sufficiently flexible to adapt to an unknown pathogen. Director of the US National Institute of Allergy and Infectious Diseases Anthony Fauci stated that the concept of Disease X would encourage WHO projects to focus their research efforts on entire classes of viruses, instead of just individual strains, thus improving WHO capability to respond to unforeseen strains. In 2020, it was speculated, including among some of the WHO's own expert advisors, that COVID-19, caused by SARS-CoV-2 virus strain, met the requirements to be the first Disease X.

Inovio Pharmaceuticals formerly known as Electrofect founded in 1999 renamed to Inovio in October 2001 is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.

Richard Hatchett American epidemiologist

Richard Hatchett is an American oncologist and epidemiologist who has been serving as chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI) in Oslo and London since 2017. He was awarded the Secretary of Health and Human Services’s Award for Distinguished Service.

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID‑19. The COVID‑19 vaccines are widely credited for their role in reducing the severity and death caused by COVID‑19.

COVID-19 Solidarity Response Fund is a global fund for supporting the work of the World Health Organization (WHO) in containing the COVID-19 pandemic. It was launched on 13 March 2020 by the United Nations Foundation and the Swiss Philanthropy Foundation in support of WHO, and was announced by the Director-General of WHO in Geneva, Switzerland. The purpose of the response fund is to "support WHO’s work, including with partners, to track and understand the spread of the virus; to ensure patients get the care they need and frontline workers get essential supplies and information; and to accelerate research and development of a vaccine and treatments for all who need them." Major companies, including Facebook, H&M, and Google have donated to the Solidarity Response Fund, in addition to several hundred thousand private individuals.

COVID-19 drug development Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

Impact of the COVID-19 pandemic on science and technology Effects or disruption to science, space and technology projects globally due to the COVID-19 pandemic economic shutdown

The COVID-19 pandemic has affected many scientific and technical institutions globally, resulting in lower productivity in a number of fields and programs. However, the impact of the pandemic has led to the opening of several new research funding lines for government agencies around the world.

Planning and preparing for pandemics has happened in countries and international organizations. The World Health Organization writes recommendations and guidelines, though there is no sustained mechanism to review countries' preparedness for epidemics and their rapid response abilities. National action depends on national governments. In 2005–2006, prior to the 2009 swine flu pandemic and during the decade following it, the governments in the United States, France, UK, and others managed strategic health equipment stocks, but they often reduced stocks after the 2009 pandemic in order to reduce costs.

Access to COVID-19 Tools Accelerator G20 COVID-19 global initiative

The Access to COVID-19 Tools Accelerator, or the Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines, is a G20 initiative announced by pro-tem Chair Mohammed al-Jadaan on 24 April 2020. A call to action was published simultaneously by the World Health Organization (WHO) on 24 April.

Operation Warp Speed American public–private partnership designed to accelerate COVID-19 vaccine development

Operation Warp Speed (OWS) was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The first news report of Operation Warp Speed was on April 29, 2020, and the program was officially announced on May 15, 2020. It was headed by Moncef Slaoui from May 2020 to January 2021 and by David A. Kessler from January to February 2021. At the end of February 2021, Operation Warp Speed was transferred into the responsibilities of the White House COVID-19 Response Team.

Economics of vaccines

Vaccine development and production is economically complex and prone to market failure. Many of the diseases most demanding a vaccine, including HIV, malaria and tuberculosis, exist principally in poor countries. Pharmaceutical firms and biotechnology companies have little incentive to develop vaccines for these diseases because there is little revenue potential. Even in more affluent countries, financial returns are usually minimal and the financial and other risks are great.

Deployment of COVID-19 vaccines Distribution and administration of COVID-19 vaccinations

As of 1 December 2021, 8.03 billion COVID-19 vaccine doses have been administered worldwide, with 54.5 percent of the global population having received at least one dose. While 32.52 million vaccines were then being administered daily, only 6 percent of people in low-income countries had received at least a first vaccine by October 2021, according to official reports from national health agencies, which are collated by Our World in Data.

History of COVID-19 vaccine development Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering the urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

Inovio COVID-19 vaccine COVID-19 vaccine candidate

Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.

GBP510 Vaccine candidate against COVID-19

GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.

References

  1. 1 2 3 4 5 6 "A global coalition to create new vaccines for emerging infectious diseases". cepi.net. January 18, 2017. Archived from the original on March 22, 2021. Retrieved March 9, 2021. CEPI is a direct response to calls from four independent expert reports into the Ebola epidemic for a new system for stimulating the development of vaccines against epidemic threats. It was founded by the governments of India and Norway, the Bill & Melinda Gates Foundation, Wellcome and the World Economic Forum, which has played a key convening role, bringing together stakeholders at the 2016 Davos meeting and other events.
  2. "Who we are". cepi.net. Archived from the original on June 11, 2020.
  3. 1 2 3 4 5 6 7 8 9 10 11 Clive Cookson (January 18, 2017). "Davos launch for coalition to prevent epidemics of emerging viruses". Financial Times . Archived from the original on April 2, 2020. Retrieved March 6, 2020. Billion-dollar programme aims to cut vaccine-development time from 12 years to one
  4. 1 2 3 4 5 6 7 8 9 Peter Coy (February 13, 2020). "The Road to a Coronavirus Vaccine Runs Through Oslo". Bloomberg News . Archived from the original on March 20, 2020. Retrieved March 7, 2020.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Dimitrios Gouglas; Mario Christodoulou; Stanley A Plotkin; Richard Hatchett (November 2019). "CEPI: Driving Progress Towards Epidemic Preparedness And Response". Epidemiologic Reviews . 41 (1): 28–33. doi:10.1093/epirev/mxz012. PMC   7108492 . PMID   31673694.
  6. 1 2 Bernasconi, Valentina; Kristiansen, Paul A.; Whelan, Mike; Román, Raúl Gómez; Bettis, Alison; Yimer, Solomon Abebe; Gurry, Céline; Andersen, Svein R.; Yeskey, Debra; Mandi, Henshaw; Kumar, Arun; Holst, Johan; Clark, Carolyn; Cramer, Jakob P.; Røttingen, John-Arne; Hatchett, Richard; Saville, Melanie; Norheim, Gunnstein (2020). "Developing vaccines against epidemic-prone emerging infectious diseases". Bundesgesundheitsblatt. 63 (1): 65–73. doi:10.1007/s00103-019-03061-2. PMC   6925075 . PMID   31776599.
  7. 1 2 3 John Cohen (September 2, 2016). "New vaccine coalition aims to ward off epidemics". Science . 353 (6303). Archived from the original on September 6, 2016. Retrieved September 5, 2016.
  8. 1 2 3 4 5 6 Gerald Posner (March 2, 2020). "Big Pharma May Pose an Obstacle to Vaccine Development". The New York Times . Archived from the original on March 7, 2020. Retrieved March 8, 2020. Drug companies on CEPI's scientific advisory panel, including Johnson & Johnson, Pfizer, and Japan's Takeda, pushed back. CEPI mostly capitulated in a December 2018 two-page declaration in which it jettisoned specifics but gave lip service to its founding mission of "equitable access to these vaccines for affected populations during outbreaks."
  9. 1 2 Stanley A. Plotkin; Adel A.F. Mahmoud; Jeremy Farrar (July 23, 2015). "Establishing a Global Vaccine-Development Fund" (PDF). The New England Journal of Medicine . 373 (4): 297–300. doi: 10.1056/NEJMp1506820 . PMID   26200974. Archived (PDF) from the original on May 5, 2017. Retrieved April 10, 2020.
  10. Alexandra Sifferlin (January 19, 2017). "This New Group Wants to Stop Pandemics Before They Start". Time . Archived from the original on March 3, 2020. Retrieved March 8, 2020.
  11. Paton, James (January 18, 2017). "Ebola, Zika Push Drugmakers into Effort to Avert Pandemics". Bloomberg . Archived from the original on February 8, 2017. Retrieved February 7, 2017.
  12. "Putting shots in the locker". The Economist . 420 (9003). September 3, 2016. pp. 67–68. Archived from the original on August 1, 2017. Retrieved August 25, 2017.
  13. Natalina Lopez (January 27, 2017). "The Top 10 Moments at the 2017 Davos World Economic Forum". Town & Country . Archived from the original on February 6, 2017. Retrieved March 13, 2020.
  14. Michael Dumiak (2017). "AN INTERVIEW WITH RICHARD HATCHETT". IAVIReport . 21 (1). Archived from the original on April 14, 2020. Retrieved March 7, 2020.
  15. 1 2 3 4 Hannah Kuchler (January 30, 2020). "The scientist leading the coronavirus vaccine race". Financial Times . Archived from the original on April 2, 2020. Retrieved March 8, 2020.
  16. "Richard Hatchett at LSHTM". London School of Hygiene & Tropical Medicine . Archived from the original on March 29, 2020. Retrieved March 8, 2020.
  17. "Coalition for Epidemic Preparedness Innovations". CEPI. Archived from the original on March 8, 2020. Retrieved March 11, 2020.
  18. 1 2 Butler, Declan (January 18, 2017). "Billion-dollar project aims to prep vaccines before epidemics hit". Nature . 541 (7638): 444–445. Bibcode:2017Natur.541..444B. doi: 10.1038/nature.2017.21329 . PMID   28128262.
  19. 1 2 Laura Spinney (March 15, 2020). "When will a coronavirus vaccine be ready?". The Guardian . Archived from the original on March 16, 2020. Retrieved March 15, 2020. "The speed with which we have [produced these candidates] builds very much on the investment in understanding how to develop vaccines for other coronaviruses", says Richard Hatchett, CEO of the Oslo-based nonprofit the Coalition for Epidemic Preparedness Innovations (Cepi), which is leading efforts to finance and coordinate Covid-19 vaccine development.
  20. 1 2 Lena H. Sun (January 18, 2017). "New global coalition launched to create vaccines, prevent epidemics". The Washington Post . Archived from the original on April 10, 2020. Retrieved March 12, 2020.
  21. "Coalition for Epidemic Preparedness Innovation turns to IFFIm to accelerate funding for new vaccine development". GAVI . December 12, 2018. Archived from the original on April 10, 2020. Retrieved March 8, 2020. Under the just-approved arrangement, IFFIm will, on CEPI's behalf, issue bonds on international capital markets supported by new pledges from the Kingdom of Norway, which hosts CEPI. Norway and CEPI have turned to IFFIm because of its simplicity, speed of execution, cost, compliance and strong reputation among investors.
  22. "IFFIm issues NOK600 million Vaccine Bonds". International Finance Facility for Immunisation . July 18, 2019. Archived from the original on May 27, 2020. Retrieved March 8, 2020.
  23. "FPA-SC1-CEPI-2019 – Grant to the Coalition for Epidemic Preparedness Innovations (CEPI)". European Commission . March 19, 2019. Retrieved March 9, 2020.
  24. Dimitrios Gouglas (April 13, 2019). "[PRESENTATION] Coalition for Epidemic Preparedness Innovations" (PDF). Unite For Sight . Retrieved March 12, 2020.
  25. Rhys Blakely (March 27, 2020). "UK promises £210m to find coronavirus vaccine". The Times . Archived from the original on March 28, 2020. Retrieved March 28, 2020.
  26. Andrew Woodcock (March 27, 2020). "Coronavirus: Britain now the largest contributor to international effort to find vaccine after £210m commitment". The Independent . Archived from the original on March 27, 2020. Retrieved March 28, 2020.
  27. "Annual Progress Report" (PDF). CEPI. March 31, 2020.
  28. "The Right Shot: Bringing down barriers to affordable and adapted vaccines – 2nd Ed., 2015". Médecins Sans Frontières Access Campaign. Archived from the original on March 22, 2020. Retrieved April 10, 2020.
  29. "Original CEPI Policy Documentation" (PDF). Médecins Sans Frontières. Archived (PDF) from the original on March 31, 2020. Retrieved April 10, 2020.
  30. 1 2 3 Huneycutt, Brenda; Lurie, Nicole; Rotenberg, Sara; Wilder, Richard; Hatchett, Richard (February 2020). "Finding equipoise: CEPI revises its equitable access policy". Vaccine. 38 (9): 2144–2148. doi:10.1016/j.vaccine.2019.12.055. PMC   7130943 . PMID   32005536.
  31. 1 2 3 "MSF's response to CEPI's policy regarding equitable access". Médecins Sans Frontières Access Campaign. Archived from the original on April 10, 2020. Retrieved April 10, 2020.
  32. "Open letter to CEPI Board Members: Revise CEPI's access policy". Médecins Sans Frontières Access Campaign. Archived from the original on April 10, 2020. Retrieved April 10, 2020.
  33. "Norway has invested 200 million euros in epidemic preparedness, but are they getting what they're paying for?". Médecins Sans Frontières Access Campaign. Archived from the original on April 10, 2020. Retrieved April 10, 2020.
  34. Lei Ravelo, Jenny (March 11, 2019). "Battle over CEPI's access to vaccines policy deepens". Devex. Archived from the original on April 10, 2020. Retrieved April 30, 2020.
  35. 1 2 Gulland, Anne (June 25, 2019). "Warning over lack of transparency in the development of vaccines". The Daily Telegraph. Archived from the original on May 17, 2020. Retrieved April 30, 2020.
  36. "The wrong prescription for vaccine access". Médecins Sans Frontières Access Campaign. Archived from the original on April 10, 2020. Retrieved April 10, 2020.
  37. "Flere fredsprisforslag før fristen gikk ut". Aftenposten . Norwegian News Agency. January 31, 2021.
  38. "Hektisk nomineringsaktivitet før fredsprisfrist". Dagsavisen . January 31, 2021.
  39. 1 2 3 4 5 "Who we are". Coalition for Epidemic Preparedness Innovations. Archived from the original on March 8, 2020. Retrieved March 9, 2020.
  40. Gouglas, D.; Thanh Le, T.; Henderson, K.; Kaloudis, A.; Danielsen, T.; Hammersland, N. C.; Robinson, J. M.; Heaton, P. M.; Røttingen, J. A. (2018). "Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study". The Lancet. 6 (12): e1386–e1396. doi: 10.1016/S2214-109X(18)30346-2 . PMC   7164811 . PMID   30342925.
  41. "CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS – Press Release". Archived from the original on April 16, 2018. Retrieved April 15, 2018.
  42. "Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS – Press Release". GlobeNewswire News Room. Archived from the original on April 14, 2018. Retrieved April 15, 2018.
  43. "CEPI awards up to US$43.6 million to Public Health Vaccines, LLC. for development of a single-dose Nipah virus vaccine candidate". CEPI. August 19, 2019. Retrieved March 9, 2020.
  44. 1 2 Steenhuysen, Julie; Kelland, Kate (January 24, 2020). "With Wuhan virus genetic code in hand, scientists begin work on a vaccine". Thomson Reuters. Archived from the original on January 25, 2020. Retrieved January 25, 2020.
  45. 1 2 Devlin, Hannah (January 24, 2020). "Lessons from Sars outbreak help in race for coronavirus vaccine". The Guardian . Archived from the original on January 25, 2020. Retrieved January 25, 2020.
  46. "Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego". Los Angeles Times . February 15, 2020. Archived from the original on February 16, 2020. Retrieved February 17, 2020.
  47. Mazumdar T (January 30, 2020). "Coronavirus: Scientists race to develop a vaccine". BBC News Online . Archived from the original on January 30, 2020. Retrieved February 3, 2020.
  48. "CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019". CureVac AG. January 31, 2020. Archived from the original on February 25, 2020. Retrieved February 25, 2020.
  49. Andrew Dunne (January 23, 2020). "A coalition backed by Bill Gates is funding biotechs that are scrambling to develop vaccines for the deadly Wuhan coronavirus". Business Insider . Archived from the original on March 6, 2020. Retrieved March 8, 2020.
  50. Julia Belluz; Umair Irfan; Brian Resnick (March 6, 2020). "A simple guide to the vaccines and drugs that could fight coronavirus". Vox . Archived from the original on March 6, 2020. Retrieved March 8, 2020. Knowing there will be more Ebola-like emergencies in need of ready vaccines was the starting point for the Coalition for Epidemic Preparedness Innovations, or CEPI, a public-private partnership that launched in 2017. Their raison d'être: to award grants for swift vaccine development targeting emerging threats that the pharmaceutical industry might otherwise ignore.
  51. Matt Frei (March 6, 2020). "'This is the most frightening disease I've ever encountered' – virus expert Dr. Richard Hatchett". Channel 4 News . Interview on C4 News [VIDEO]. Archived from the original on March 7, 2020. Retrieved March 8, 2020. Dr. Richard Hatchett advised the Bush and Obama White Houses and worked for the agency that protects Americans against pandemics and bioweapons.
  52. Robert Mendick (March 6, 2020). "Coronavirus poses most serious threat to public health since Spanish flu pandemic, says expert". The Daily Telegraph . Archived from the original on March 7, 2020. Retrieved March 7, 2020.
  53. Kate Kelland (March 6, 2020). "$2 billion needed to develop COVID-19 shot, says epidemic response group". Reuters News . Archived from the original on March 7, 2020. Retrieved March 7, 2020.
  54. Hannah Kultcher (March 5, 2020). "Coronavirus and the $2bn race to find a vaccine". Financial Times . Archived from the original on March 6, 2020. Retrieved March 7, 2020.
  55. James Paton (March 6, 2020). "Coronavirus Vaccine Work Faces Funding Gap of Almost $2 Billion". Bloomberg News . Archived from the original on March 7, 2020. Retrieved March 8, 2020.
  56. Kate Kelland (March 9, 2020). "Epidemic response group ups coronavirus vaccine funding to $23.7 million". Reuters News . Archived from the original on March 10, 2020. Retrieved March 9, 2020.